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Objectives The purpose of this study was to examine the incidence of nuisance bleeding after AMI and its impact on QOL.
Background Prolonged dual antiplatelet therapy (DAPT) is recommended after acute myocardial infarction (AMI) to reduce
ischemic events, but it is associated with increased rates of major and minor bleeding. The incidence of even
lesser degrees of post-discharge “nuisance” bleeding with DAPT and its impact on quality of life (QOL) are
unknown.
Methods Data from the 24-center TRIUMPH (Translational Research Investigating Underlying Disparities in Acute Myocar-
dial Infarction Patients’ Health Status) study of 3,560 patients, who were interviewed at 1, 6, and 12 months
after AMI, were used to investigate the incidence of nuisance bleeding (defined as Bleeding Academic Research
Consortium type 1). Baseline characteristics associated with “nuisance” bleeding and its association with QOL,
as measured by the EuroQol 5 Dimension visual analog scale, and subsequent re-hospitalization were examined.
Results Nuisance (Bleeding Academic Research Consortium type 1) bleeding occurred in 1,335 patients (37.5%) over
the 12 months after AMI. After adjusting for baseline bleeding and mortality risk, ongoing DAPT was the stron-
gest predictor of nuisance bleeding (rate ratio [RR]: 1.44, 95% confidence interval [CI]: 1.17 to 1.76 at 1 month;
RR: 1.89, 95% CI: 1.35 to 2.65 at 6 months; and RR: 1.39, 95% CI: 1.08 to 1.79 at 12 months; p  0.01 for all
comparisons). Nuisance bleeding at 1 month was independently associated with a decrement in QOL at 1 month
(2.81 points on EuroQol 5 Dimension visual analog scale; 95% CI: 1.09 to 5.64) and nonsignificantly toward
higher re-hospitalization (hazard ratio: 1.20; 95% CI: 0.95 to 1.52).
Conclusions Nuisance bleeding is common in the year after AMI, associated with ongoing use of DAPT, and independently
associated with worse QOL. Improved selection of patients for prolonged DAPT may help minimize the incidence
and adverse consequences of nuisance bleeding. (J Am Coll Cardiol 2013;61:2130–8) © 2013 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.044and the National Cancer Institute of the National Institutes of Health, Grant
1KM1CA156708-01. Dr. Yeh has received research funding from the Harvard
Clinical Research Institute. Dr. Kosiborod has received research grant support from
Medtronic Minimed, Gilead Sciences, Genentech, Sanofi-Aventis, and GluMetrics
Inc.; and serves as a consultant and is on the advisory board for Medtronic Minimed,
Gilead Sciences, Genentech, Boehringer Ingelheim, CardioMEMS, and Hoffmann-
La Roche Ltd. Dr. Wang is a consultant for ACCF and Medeo; lectures for
AstraZeneca; and has received research grant support from Bristol-Myers Squibb,
Daiichi Sankyo, Heartscape Technologies, Eli Lilly & Company, Sanofi-Aventis,
Schering Plough/Merck, and Gilead. Dr. Cohen serves as a consultant and is on the
advisory board of AstraZeneca and Janssen Pharmaceuticals; has received researchFrom the *Cardiovascular Division, Washington University School of Medicine, St.
Louis, Missouri; †Barnes-Jewish Hospital, St. Louis, Missouri; ‡Saint Luke’s Mid
America Heart Institute, Kansas City, Missouri; §The University of Missouri –
Kansas City, Kansas City, Missouri; Cardiology Division, Department of Medicine,
Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts;
and the ¶Division of Cardiology, Duke University Medical Center, Durham, North
Carolina. The TRIUMPH study was funded by P50 HL077113 from the National
Heart, Lung, and Blood Institute, and support for these analyses was provided by an
award from the American Heart Association Pharmaceutical Round Table and David
and Stevie Spina. Dr. Amin is funded via a comparative effectiveness research KM1
career development award from the Clinical and Translational Science Award
program of the National Center for Advancing Translational Sciences of the National
Institutes of Health, Grants UL1TR000448, KL2TR000450, and TL1TR000449,
grant support from Boston Scientific, Medtronic, Abbott Vascular, Eli Lilly, Daichi
Sankyo, Accumetrix, BMS/Sanofi, Schering-Plough, AstraZeneca, and Edwards
2131JACC Vol. 61, No. 21, 2013 Amin et al.
May 28, 2013:2130–8 Nuisance Bleeding After AMIThe treatment of acute myocardial infarction (AMI) and
chronic ischemic heart disease entails a careful balance be-
tween maximizing antiplatelet therapy to minimize ischemic
events (1) while avoiding bleeding (2–5). The incidence and
prognostic importance of major and minor bleeding after
AMI or percutaneous coronary intervention (PCI) are well
recognized (6–10). Clinical predictors of in-hospital bleed-
ing have been defined, and its risk can be estimated using
validated risk scores, such as the CRUSADE (Can Rapid Risk
Stratification of Unstable Angina Patients Suppress Adverse
Outcomes With Early Implementation of the ACC/AHA
Guidelines) bleeding model (11,12). In contrast, little is known
See page 2139
about post-discharge bleeding, including “nuisance” bleeding,
which can be defined as easy bleeding, bruising, and nose or
gum bleeds. The importance of this more minor degree of
bleeding was recently underscored by the Bleeding Aca-
demic Research Consortium (BARC) definition of bleeding
(13), which defined BARC type 1 bleeding as “bleeding that
does not cause the patient to seek medical care by a
healthcare professional or hospitalization, and is not action-
able” but may still be significant from patients’ perspectives.
The prevalence, predictors, and impact of nuisance bleeds
on outcomes after AMI are currently unknown.
What few reports (14,15) do exist on the long-term
incidence and consequences of nuisance bleeding are limited
to single-center experiences of lower-risk patients after PCI,
where it has been suggested that post-discharge nuisance
bleeding is common and potentially associated with adverse
cardiac events. No report has ever examined the association
of nuisance bleeding with patients’ quality of life (QOL).
To better address the existing gap in knowledge in the
prevalence, predictors, and consequences of nuisance bleed-
ing in the setting of AMI, we examined data from the
prospective multicenter, TRIUMPH (Translational Research
Investigating Underlying Disparities in Acute Myocardial
Infarction Patients’ Health Status) study (16), which in-
cluded detailed follow-up of patients’ self-reported bleed-
ing events and QOL. We sought to clarify the magnitude
and significance of nuisance bleeding after AMI. We
investigated the incidence of nuisance bleeding after
AMI in TRIUMPH, its predictors including its associ-
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2013, accepted February 14, 2013.ation with ongoing dual anti-
platelet therapy (DAPT) use
during follow-up, and its impact
on health-related QOL and sub-
sequent re-hospitalization events.
Methods
The TRIUMPH population.
The TRIUMPH study is a pro-
spective, multicenter cohort study of
4,340 patients with AMI (both
non–ST-segment and ST-segment
elevation myocardial infarction) en-
rolled at 24 US centers between
April 11, 2005, and December
31, 2008 (16). Patients were eligi-
ble for inclusion in the TRIUMPH
study if they were aged 18 years
and had an AMI, supported by el-
evated biomarkers and either
electrocardiographic changes or
symptoms consistent with the di-
agnosis (16). Patients were not
eligible for enrollment if they were transferred to the
participating hospital from another facility 24 h after their
original AMI presentation, refused, were incarcerated, or could
not provide informed consent. TRIUMPH was approved by
the institutional review boards at each participating site, and
written informed consent was obtained from all participants.
Study population. For the purposes of this study, we
included patients who had at least one follow-up visit after
the index AMI hospitalization at 1, 6, or 12 months from
which information on patient-reported bleeding events and
DAPT use was recorded.
Predictors and outcomes. In TRIUMPH, nuisance bleed-
ing was assessed via the following 4 questions at 1-, 6-, and
12-month interviews: “Since leaving the hospital after your
heart attack, have you had: 1) easy or significant bleeding?
2) significant bruising? 3) gum bleeds or nose bleed?
4) serious bleeding?” We applied the newly developed
BARC bleeding definition (13) as a framework to define the
primary predictor variable of interest, nuisance bleeding
(BARC type 1), as the occurrence of any of the 4 bruising/
bleeding events that did not lead to: 1) hospitalization
(BARC type 2 or higher bleeding, n  13), 2) blood
transfusion (BARC type 3 or higher bleeding, n  27), or
3) change of medications by a physician (BARC type 2 or
higher bleeding, n 32). The final analytic cohort included
3,560 patients.
Health-related QOL was the main outcome of interest.
The EuroQol 5 Dimension (EQ-5D) instrument was used
to assess QOL in the TRIUMPH study. The EQ-5D is a
generic measure of health status developed by the EuroQoL
group (17), which measures health status in 5 dimensions:
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
BARC  Bleeding
Academic Research
Consortium
CABG  coronary artery
bypass grafting
CI  confidence interval
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ing levels: 1) no problems, 2) some problems, 3) extreme
problems. The patients also estimate their total health status
on a 20-cm visual analog scale (VAS) with the endpoints
being “best imaginable health state”  a score of 100 and
“worst imaginable health state”  a score of 0 (17). The
Q-5D VAS is thus a quantitative measure of patients’
erceived health, a patient-centered health outcome. The
Q-5D has been validated for patients with acute coronary
yndrome (18,19). Re-hospitalization at 1 year was a sec-
ndary outcome of interest. Trained data collectors tracked
e-hospitalization events, which were then centrally adjudi-
ated independently of the site investigator(s).
tatistical analyses. Baseline clinical and demographic
haracteristics of patients who reported nuisance bleeding
ersus those who did not were compared using the chi-
quare or Fisher exact test for categoric variables, as appro-
riate. Independent t tests or Mann–Whitney Wilcoxon U
tests were used to compare continuous variables. Indepen-
dent correlates of nuisance bleeding were determined using
a multivariable, repeated measures, modified Poisson re-
gression model with robust variance estimation (20). A
repeated-measures approach was chosen because repeated
measurements within a cluster (e.g., a person’s likelihood to
bleed over time intervals) are more correlated than measure-
ments in different clusters. A repeated-measures design
offers the advantage of controlling for within-subject vari-
ance (the tendency to bleed) and is a more conservative
analytic approach. We modeled nuisance bleeding at 1, 6,
and 12 months as the dependent variable (repeated mea-
sures). A key predictor variable of interest was DAPT
therapy at 1, 6, or 12 months. For patients discharged with
DAPT therapy and continuing to report DAPT use at 1, 6,
or 12 months, we assumed continued use of DAPT between
assessments. Other covariates included confounders of
bleeding, such as age, female gender, insurance status,
GRACE (Global Registry of Acute Coronary Events)
6-month mortality risk score (21), CRUSADE bleeding
risk score (12), history of atrial fibrillation, occurrence of
in-hospital bleeding, baseline hemoglobin and creatinine,
development of atrial fibrillation or warfarin use during the
initial AMI hospitalization, or coronary artery bypass graft-
ing (CABG) at the time of the initial AMI. We explored
interactions of every covariate with the 3 time points and
included the following 3 significant time interactions:
CABG during the initial AMI hospitalization, atrial fibril-
lation or warfarin use during the initial AMI hospitaliza-
tion, and baseline creatinine. In this repeated-measures
modeling approach, exposure to clopidogrel during the 3
time points (1, 6, and 12 months) was matched with
bleeding during the corresponding time intervals, and it
preserved the temporal association between the exposure
and the outcome during the corresponding time intervals.
The association of self-reported bleeding at 1 month with
1-month health status outcomes was evaluated using hier-
archical (adjusting for site as a random effect) multivariablelinear regression model for the EQ-5D health status out-
come. This model adjusted for the baseline health status
EQ-5D VAS score, age (per 10 years), female gender,
insurance status, in-hospital PCI, in-hospital CABG,
GRACE 6-month mortality risk score, CRUSADE bleed-
ing risk score, warfarin use, history of atrial fibrillation,
occurrence of in-hospital bleeding, baseline hemoglobin,
and baseline creatinine.
As a secondary analysis, the association of nuisance
bleeding at 1 month with subsequent (beyond 1 month) re-
hospitalization during the 12-month follow-up period was
assessed by using Kaplan-Meier survival analysis and com-
pared using the log-rank test. Multivariable Cox regression,
stratified by site and adjusting for the listed confounders
associated with bleeding, mortality, and re-hospitalization,
was performed to identify the independent association of
nuisance bleeding at 1 month with subsequent re-
hospitalization. We also examined the association of early
nuisance bleeding at 1 month after discharge with future
more serious Thrombolysis In Myocardial Infarction
(TIMI) major or minor bleeding, as well as nuisance
bleeding (at 6 or 12 months).
Results
Of the 3,560 included patients with AMI, 1,335 (37.5%)
reported a nuisance (BARC type I) bleeding episode during
the 12-month follow-up period. Most nuisance bleeding
occurred early, at 1 month (n  864; 64.7% of all reports of
bleeding); nevertheless, nuisance bleeding continued to
occur throughout the 12 months of follow-up (n  338,
25.3% at 6 months; n  476, 35.7% at 12 months). The
most common type of nuisance bleeding reported was
“bruising and bleeding” (n  714, 53.5% at 1 month; n 
272, 20.4% at 6 months; n  412, 30.9% at 12 months).
In unadjusted analyses, patients with nuisance bleeding were
more likely to be older, to be female, to have experienced severe
bleeding at the time of their initial hospitalization, and to have
had a higher CRUSADE bleeding risk score. Patients with
nuisance bleeding also were more likely to have a history of or
develop atrial fibrillation during hospitalization or follow-up
and more likely to be initiated on warfarin at discharge or
during follow-up (Table 1).
Association of DAPT with nuisance bleeding. In unad-
justed analysis, DAPT use at discharge was more common
among patients who developed nuisance bleeding than in
those who did not (85.0% vs. 72.4%, p 0.001). DAPT use
at 1, 6, and 12 months was strongly associated with nuisance
bleeding (Table 1). In multivariable analyses, ongoing DAPT
was strongly and independently associated with an approxi-
mately 2-fold higher risk of nuisance bleeding. This association
was present even after adjustment for the CRUSADE bleed-
ing risk score, the GRACE mortality risk score, atrial
fibrillation, warfarin use, and other covariates (Fig. 1).
Other variables independently associated with nuisance
h
p
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confidence interval [CI]: 1.19 to 1.40, p  0.0001) and
istory of atrial fibrillation (RR: 1.35, 95% CI: 1.15 to 1.57,
Baseline Clinical and Demographic Characteristby Nu sance Bleeding at Any Time PointTable 1 as li e Clinical and Demograph cby Nuisance Bleeding at Any Time
N
(n 
Sociodemographics
Age, yrs 59.
Sex
Male 83
Female 50
Race
White/Caucasian 1,03
Black/African American 20
Other 9
Education, more than high school 71
No insurance/self-pay 24
BMI, kg/m2 29.
Risk factors
Diabetes 36
Dyslipidemia 65
Hypertension 86
Chronic heart failure 8
Peripheral vascular disease 6
Prior CAD (MI/PCI/CABG) 40
Prior CVA 6
Chronic kidney disease 8
Atrial fibrillation 7
Disease severity and therapies
CRUSADE bleeding risk score 25.
GRACE 6-month mortality risk score 99.
Final MI diagnosis
STEMI 62
NSTEMI 70
In-hospital PCI 98
Drug-eluting stent 55
In-hospital CABG 8
In-hospital bleeding 15
In-hospital bleeding class
TIMI major 2
TIMI minor 5
TIMI minimal 7
Warfarin at discharge 18
Warfarin at 1 month 15
Warfarin at 6 month 9
Warfarin at 1 year 7
Warfarin at DC or in-hospital AF 22
Thienopyridine at DC 1,13
Thienopyridine at 1 month 86
Thienopyridine at 6 month 73
Thienopyridine at 1 year 67
Values are mean  SD or n (%).
AF  atrial fibrillation; BMI  body mass index; CABG  coronary ar
Risk Stratification of Unstable Angina Patients Suppress Adverse O
cerebrovascular accident; DC  discharge; GRACE  Global Registry o
MI  myocardial infarction; PCI  percutaneous coronary interven
myocardial infarction. 0.0002).Association of nuisance bleeding with quality of life. Pa-
tients who developed nuisance bleeding had more pain/
discomfort and anxiety/depression, and an overall lower
acteristics
e Bleeding at Any Time Point
p Value5)
No
(n  2,225)
.2 59.0 11.9 0.102
0.001
%) 1,552 (69.8%)
%) 673 (30.2%)
0.001
%) 1,444 (65.1%)
%) 636 (28.7%)
) 138 (6.2%)
%) 1,084 (49.0%) 0.009
%) 508 (23.2%) 0.002
4 29.8 6.5 0.109
%) 689 (31.0%) 0.025
%) 1,110 (49.9%) 0.665
%) 1,481 (66.6%) 0.371
) 176 (7.9%) 0.087
) 107 (4.8%) 0.984
%) 699 (31.4%) 0.562
) 98 (4.4%) 0.345
) 147 (6.6%) 0.712
) 86 (3.9%) 0.015
.2 24.8 15.0 0.048
.7 100.2 28.8 0.395
0.012
%) 950 (42.7%)
%) 1,275 (57.3%)
%) 1,399 (62.9%) 0.001
%) 847 (38.1%) 0.043
) 255 (11.5%) 0.001
%) 207 (9.3%) 0.027
0.039
%) 52 (25.1%)
%) 70 (33.8%)
%) 85 (41.1%)
5%) 181 (8.1%) 0.001
5%) 122 (5.5%) 0.001
%) 104 (4.7%) 0.003
%) 77 (3.5%) 0.001
8%) 270 (12.1%) 0.001
9%) 1,595 (71.7%) 0.001
1%) 985 (66.4%) 0.001
3%) 878 (62.8%) 0.001
6%) 705 (56.5%) 0.001
pass grafting; CAD  coronary artery disease; CRUSADE  Can Rapid
es With Early Implementation of the ACC/AHA Guidelines; CVA 
Coronary Events; NSTEMI  non–ST elevation myocardial infarction;
EMI  ST elevation myocardial infarction; TIMI  thrombolysis inicsChar
Point
uisanc
Yes
1,33
7 12
2 (62.3
3 (37.7
5 (77.7
3 (15.2
4 (7.1%
2 (53.5
6 (18.8
4 6.
6 (27.4
6 (49.1
9 (65.1
5 (6.4%
4 (4.8%
7 (30.5
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4 (6.3%
5 (5.6%
9 15
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8 (47.0
7 (53.0
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Nuisance Bleeding After AMI May 28, 2013:2130–8Adjusted, multivariable analysis showed that nuisance
bleeding by 1 month was associated with a significant
decline of 2.81 EQ-5D VAS score points (95% CI: 0.84 to
4.79 points) at 1 month that was independent of baseline
QOL and other covariates (Fig. 2).
Association of nuisance bleeding with subsequent re-
hospitalization. In unadjusted Kaplan-Meier analyses, pa-
tients with nuisance bleeding at 1 month were more likely to
experience re-hospitalization by 12 months (Fig. 3A).
However, after multivariable adjustment in Cox propor-
tional hazards regression analysis, this association was at-
tenuated and no longer significant (hazard ratio: 1.20, 95%
CI: 0.95 to 1.52, p  0.13) (Fig. 3B).
Association of nuisance bleeding with overt bleeding.
We found no association of nuisance bleeding within the
first 30 days of discharge with more severe TIMI major or
minor bleeding during subsequent follow-up (0.2% in the
no nuisance bleeding group vs. 1.35% in the nuisance
bleeding group, log-rank test p  0.057, adjusted hazard
ratio: 3.12, 95% CI: 0.33 to 29.34, p  0.32). However, we
ound an association of 1-month nuisance bleeding with
ubsequent nuisance bleeding; subjects with nuisance bleed-
ng at 1 month were twice as more likely to develop subsequent
uisance bleeding at 6 or 12 months (62.5%) than those who did
ot have nuisance bleeding at 1 month (38.25%) (adjusted RR:
.61, 95% CI: 1.39 to 1.86, p  0.0001). In TRIUMPH, 202
atients (5.7%) had an in-hospital TIMI major or minor
leeding event during the index AMI admission before
ospital discharge. After excluding this group of patients,
he incidence of nuisance bleeding during follow-up re-
ained unchanged, from 1,335 (37.5%) in the full cohort to
Dec
DAPT effect at 1 year on 1 year nuisance bleed
DAPT effect at 6 month on 6 month nuisance bl
DAPT effect at 1 month on 1 month nuisance bl
CRUSADE score effect on nuisance bleeding ov
GRACE score effect on nuisance bleeding over 
Figure 1 Independent Association of Self-Reported Nuisance B
This is a multivariable, repeated-measures, modified Poisson regression model wi
dent variable (repeated measures), and the independent variables were those con
(DAPT) at discharge, 1 month, 6 months, or 12 months (main exposure variable),
Events) 6-month mortality risk score, CRUSADE (Can Rapid Risk Stratification of U
ACC/AHA Guidelines) bleeding risk score, history of atrial fibrillation at baseline, o
opment of atrial fibrillation or warfarin use during hospitalization, or coronary arter
three time points. Variables other than CRUSADE and GRACE risk scores not show
bleeding were female gender (rate ratio [RR]: 1.29; 95% confidence interval [CI]: 1
1.57; p  0.0002) (data not shown). X-axis graphs the RR. Numbers alongside th,255 (37.4%).iscussion
mong investigations examining the frequency and conse-
uences of bleeding for patients after hospitalization for AMI,
his is the first study to report the rates of less severe nuisance
leeding quantified within the framework of the recent BARC
leeding classification13 as BARC type 1 bleeding. By analyz-
ing data from the TRIUMPH study, a multicenter registry of
patients with AMI that collected extensive baseline and
follow-up data, we observed that approximately 40% of pa-
tients reported nuisance bleeding in the year after their AMI.
Even after adjusting for numerous patient characteristics,
including bleeding risk and other anticoagulants, there was a
strong, independent association between post-discharge nui-
sance bleeding and DAPT use. Moreover, such nuisance
bleeding was associated with a significantly worse QOL and
nonsignificantly higher rates of re-hospitalization. The clinical
significance of our observed 3-point difference in those with
and without nuisance bleeding is comparable to the difference
in osteoporotic patients with and without vertebral fractures
(22). Our findings suggest that these adverse patient experi-
ences, which are largely ignored in clinical trials, may be
important issues in clinical practice and warrant consideration
at the time of AMI treatment.
Our study extends previous observations from the ran-
domized trials of DAPT use and has potentially important
clinical implications. Previous clinical trials have reported an
excess incidence of major and minor bleeding (BARC 2 or
greater classification), but not nuisance bleeding (BARC 1).
For example, both the CREDO (Clopidogrel for the
Reduction of Events During Observation) trial (4) and the
CURE (Clopidogrel in Unstable Angina to Prevent Recur-
te Ratio (95% CI)
 risk Increased risk
1 2 4
e
1.39 (1.08, 1.79)
1.89 (1.35, 2.65)
1.44 (1.17, 1.76)
1.00 (1.00, 1.01)
1.00 (1.00, 1.00)
g With DAPT at Discharge, 1 Month, 6 Months, or 1 Year
st variance estimation. Nuisance bleeding at 1, 6, and 12 months is the depen-
d to be predictors of bleeding, including DES use, dual antiplatelet therapy
male gender, insurance status, GRACE (Global Registry of Acute Coronary
e Angina Patients Suppress Adverse Outcomes With Early Implementation of the
nce of in-hospital bleeding, baseline hemoglobin and baseline creatinine, devel-
ss grafting in-hospital and all significant interactions of the covariates with the
er statistically significant variables associated independently with nuisance
1.40; p  0.0001) and history of atrial fibrillation (RR: 1.35; 95% CI: 1.15 to
ting bars denote the corresponding rate ratios and 95% CI.Ra
reased
0.5
eed
eed
er tim
time
leedin
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sidere
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.19 to
e floarent Events) study (23) observed an absolute increase in 1%
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May 28, 2013:2130–8 Nuisance Bleeding After AMIto 2% for major bleeding in the year after the addition of
clopidogrel to aspirin. More recently, the CHARISMA
(Clopidogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management, and Avoidance) (2) and the
PRAGUE-8 (Clopidogrel Loading Dose for ad-Hoc Per-
cutaneous Coronary Intervention Immediately Following
Elective Coronary Angiography: Randomized Multicenter
Trial Comparing Pre-Treatment 6 Hours Before Every
Angiography vs. Cath-Lab Administration After Angiog-
raphy [Just Before Intervention]) trials (5) reported an
excess of bleeding with long-term clopidogrel and aspirin
therapy. The present study provides novel information by
describing the prevalence of BARC 1 bleeding events in
routine clinical care and elucidating its association with
Health Status Outcomes Measured via theEQ5D Questionnaire by Cat gories of NuisanceTable 2 Heal h Status Outcomes MeasuredEQ5D Questionnaire by Categories
Yes
EQ-5D: Pain/discomfort (baseline)
I have no pain or discomfort 79
I have moderate pain or discomfort 46
I am in extreme pain or discomfort 6
EQ-5D: Anxiety/depression (baseline)
I am not anxious or depressed 82
I am moderately anxious or depressed 42
I am extremely anxious or depressed 7
EQ-5D: VAS (baseline) 64
EQ-5D: Pain/discomfort (1 month)
I have no pain or discomfort 69
I have moderate pain or discomfort 44
I am in extreme pain or discomfort 4
EQ-5D: Anxiety/depression (1 month)
I am not anxious or depressed 77
I am moderately anxious or depressed 36
I am extremely anxious or depressed 5
EQ-5D: VAS (1 month) 72
EQ-5D: Pain/discomfort (6 months)
I have no pain or discomfort 59
I have moderate pain or discomfort 38
I am in extreme pain or discomfort 52
EQ-5D: Anxiety/depression (6 months)
I am not anxious or depressed 66
I am moderately anxious or depressed 32
I am extremely anxious or depressed 5
EQ-5D: VAS (6 months) 73
EQ-5D: Pain/discomfort (12 months)
I have no pain or discomfort 56
I have moderate pain or discomfort 43
I am in extreme pain or discomfort 7
EQ-5D: Anxiety/depression (12 months)
I am not anxious or depressed 67
I am moderately anxious or depressed 34
I am extremely anxious or depressed 5
EQ-5D: VAS (12 months) 74
Values are n (%) or mean  SD.
EQ-5D  EuroQol 5 Dimension; VAS  visual analog scale.patients’ QOL. In light of these data, discussing thedownstream risks of DAPT with patients after AMI or
drug-eluting stent (DES) implantation can better inform
them of what to expect and heighten awareness. Other
variables independently associated with nuisance bleeding
were female gender and history of atrial fibrillation, and
these patients, in particular, may be interested in consider-
ing therapies that could minimize their bleeding risks.
Our results also indicate that early nuisance bleeding
events early after discharge after AMI predict future bleed-
ing events during later follow-up. Thus, the recognition of
early nuisance bleeding after AMI could alert the clinician
to prompt closer monitoring of these patients for future
bleeding events. However, we observed no difference in the
nuisance bleeding rate after excluding those who had
inghe
isance Bleeding
ce Bleeding at Any Time Point
p Value,335) No (n  2,225)
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dict future nuisance bleeding.
These findings also have important implications for the
design of future studies and comparative effectiveness trials
of newer, more potent antiplatelet agents (24,25). Whereas
traditional studies have only emphasized clinically large
bleeding events in their outcomes assessments, we were able
to categorize more mild degrees of bleeding using patient-
reported interviews and to demonstrate a worsening of
outcomes in those who reported such events. The associa-
tion of BARC 1 bleeding with demonstrable decrements in
QOL and a trend toward increased risks of readmission
support the hierarchically graded, consensus classification
for bleeding advocated by the BARC investigators (13).
Identifying these risks of DAPT may be even more relevant
with the more potent P2Y12 inhibitors. For example, the
PLATO (PLATelet inhibition and patient Outcomes) trial,
which did not use BARC bleeding definition, found bleed-
ing rates of ticagrelor versus clopidogrel were similar to
PLATO major bleeding (11.6% vs. 11.2%; p 0.43), TIMI
ajor bleeding (7.9% vs. 7.7%, p  0.56), and the GUSTO
Global Utilization Of Streptokinase And Tpa For Oc-
luded arteries) trial severe bleeding (2.9% vs. 3.1%, p 
0.22) (26). However, these comparisons with clopidogrel
fail to quantify the potential impact of therapy on more
minor bleeding events, which we found to be common and
clinically relevant. Future studies may be improved by
incorporating follow-up questions to classify milder degrees
of nuisance bleeding (BARC 1) to provide a more complete
-10
Nuisance bleeding at 1 month
Creatinine (baseline)
Hemoglobin (baseline)
In-hospital bleeding event
History of atrial fib
Warfarin at discharge or in-hospital atrial fib
CRUSADE bleeding risk score
GRACE 6 month mortality risk score
In-hosptial CABG
In-hospital PCI
No insurance
Female gender
Age (10 year increase)
EQ5D VAS score (baseline)
Lower EQ5D
Figure 2 Independent Association of Nuisance Bleeding With Q
Estimates (with 95% CI) indicate absolute points on the EuroQol 5 Dimension visu
a multivariable, hierarchical linear regression model with EQ5D VAS score at 1 mo
able of interest. The model adjusts for other confounding variables, including age,
bleeding risk score, history of atrial fibrillation at baseline, baseline hemoglobin an
ization, or CABG in-hospital. X-axis graphs the change in QOL scores assessed via
mate with its 95% CI. PCI  percutaneous coronary intervention; other abbreviatioassessment of important patient-centered outcomes. Suchassessments also should be conducted in revascularization
trials, when DES use may mandate prolonged DAPT. As
second-generation DES platforms continue to evolve,
emerging evidence suggests that prolonged DAPT therapy
for contemporary stent designs exceeding 6 months may
have lesser benefit, while increasing rates of bleeding
(27,28). Incorporating patient-reported assessments of
BARC bleeding in DES and antiplatelet therapy trials may
therefore provide a more balanced perspective and add value
in translating this evidence to clinical practice.
Our findings have important implications for adherence
to DAPT (29). It has been reported in qualitative studies
that an important reason for DAPT discontinuation was
patients’ perception of unpleasant side effects from DAPT
(rash, bleeding, bruising) and that the majority of DAPT
continuers recalled having received education specifically on
clopidogrel adherence (30,31). Our study, which found
nuisance bleeding occurs commonly, underscores the im-
portance of educating patients to anticipate nuisance bleed-
ing and to not use that as a reason to discontinue DAPT
without talking first with their physician.
Study limitations. First, we evaluated nuisance bleeding in
the context of the BARC bleeding definitions based on
patient self-report. Although the observed association with
other adverse clinical outcomes supports the clinical signif-
icance of these reports, further validation of how best to
ascertain BARC 1 bleeding events is likely warranted.
Second, DAPT adherence rates were also self-reported, and
we did not have access to pharmacy data to quantify the
timate (95% CI)
0 5 10
-2.81 (-4.79, -0.84)
 1.08 (-0.23,  2.39)
 0.53 (-0.05,  1.11)
 0.24 (-2.89,  3.37)
-3.59 (-8.22,  1.04)
 1.62 (-1.11,  4.34)
-0.14 (-0.25, -0.03)
-0.01 (-0.08,  0.06)
-0.30 (-4.32,  3.72)
 2.64 (-0.04,  5.32)
-1.87 (-4.55,  0.80)
-0.77 (-3.38,  1.85)
 1.40 (-0.07,  2.87)
 0.30 ( 0.26,  0.35)
 score Higher EQ5D VAS score
y of Life (EQ5D VAS)
log scale (EQ5D VAS) score. Negative sign indicates a decrement in QOL. This is
the dependent variable and nuisance bleeding at 1 month as the predictor vari-
e gender, insurance status, GRACE 6-month mortality risk score, CRUSADE
eline creatinine, development of atrial fibrillation or warfarin use during hospital-
Q5D VAS. Numbers alongside the floating bars denote the corresponding esti-
in Figure 1.Es
-5
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ns asexact duration of DAPT use. It is possible that some degree
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taking DAPT regularly may be more likely to recall nui-
sance bleeding. Likewise, those not compliant with DAPT
may be less likely to report nuisance bleeding. Third, despite
multivariable adjustment of important confounders in all of
the models, there remains the possibility of unmeasured
confounding. In addition, the possibility of selection bias
due to the exclusion of 16% patients with missing follow-up
information may limit the precision and generalizability of
our estimates. Finally, despite observing a statistically sig-
nificant association between nuisance bleeding and a decre-
ment in QOL, whether this is a causal relationship is
unclear. It is possible that reduced QOL is multifactorial
and due to comorbidities other than nuisance bleeding.
Conclusions
We found that patients commonly experience nuisance
Figure 3 Association of Nuisance Bleeding With Re-Hospitaliza
(A) Kaplan-Meier survival estimates of re-hospitalization-free event rate. X-axis
tion-free. p value is for the log-rank test. (B) Cox multivariable regression mod
estimate with its 95% CI. Abbreviations as in Figure 1.bleeding after AMI. Nuisance bleeding is reported by one ofevery two to three patients and is associated with worse
QOL. Prolonged DAPT use was associated with a 1.5- to
2-fold higher risk of nuisance bleeding in the year after
AMI. These findings collectively suggest even nuisance
bleeds are significant to patients and deserve greater atten-
tion and consideration both in clinical recommendations for
treatment and in future clinical trials of prolonged anti-
thrombotic therapies.
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